FLT3 and acute myeloid leukemia: In the relapsed/refractory (R/R) setting, the second‐generation FLT3 inhibitor gilteritinib demonstrated superior efficacy over salvage chemotherapy in the Phase 3 ADMIRAL trial, significantly improving both response rates and OS in FLT3‐mutated AML [12].